In addition to developing its internal pipeline in the area of rare diseases, Ascendis Pharma seeks to maximize the value of its TransCon technology platform through partnerships with larger pharmaceutical and biotechnology companies. These collaborations are with companies who Ascendis Pharma believes will leverage the TransCon technology to address significant unmet medical needs.
Ascendis Pharma currently has two strategic collaborations together with market leaders within key therapeutic areas of significant unmet medical need. These collaborations are with Sanofi within the field of diabetes, and with Roche Genentech in the field of ophthalmology. A partnering opportunity involving TransCon Treprostinil is also currently available.
Ascendis Pharma continues to engage in partnering discussions with a range of biopharmaceutical companies, while the company also focuses on advancing its internal clinical pipeline.
Our TransCon technology platform creates novel, long-acting prodrugs of proteins, peptides and small molecules with key benefits. Learn More